To include your compound in the COVID-19 Resource Center, submit it here.
Researchers published results from a double-blind U.S. Phase II study in 47 patients that completed treatment showing that ETC-216 met
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury